Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty—results from a randomized placebo-controlled clinical trial

SUMMARY: We investigated whether the drug denosumab modulates the inflammatory response after total hip arthroplasty in a randomized controlled trial. Significantly increased expression of RANKL was found in patients treated with denosumab. This could provide an explanation for the rebound effect wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sköld, C., Kultima, K., Freyhult, E., Larsson, A., Gordh, T., Hailer, N.P., Mallmin, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463208/
https://www.ncbi.nlm.nih.gov/pubmed/35608639
http://dx.doi.org/10.1007/s00198-022-06423-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463208/
https://www.ncbi.nlm.nih.gov/pubmed/35608639
http://dx.doi.org/10.1007/s00198-022-06423-w

Ejemplares similares